As DNMT3A helps regulate DNA methylation [31], mutations in DNMT3A could cooperate with enasidenib to suppress DNA hypermethylation in patients with mutant-IDH2/DNMT3A AML. This evidence concerns the gene IDH2 and acute myeloid leukemia.